Here, we used the THY-Tau22 mouse line (Schindowski et al., 2006) as an established model of tauopathy to examine whether APPsα may modulate GSK3β and CDK5 kinase activity in vivo and ameliorate Tau-induced pathology and synaptic deficits in vivo. Here, MAPT is linked to tauopathy.